Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × Cisplatin × Clear all

NCT02595905 2026-04-08

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Phase 2 Completed

344 enrolled 11 charts

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02422498 2026-03-24

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

Phase 2 Active not recruiting

49 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT07413601 2026-02-17

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT01982448 2025-09-30

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Phase 2 Completed

147 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05174832 2023-09-28

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT03193853 2023-08-07

TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

Phase 2 Completed

12 enrolled 11 charts

Triple Negative Breast Neoplasms

NCT04297267 2022-07-22

nonpCR GP

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT02341911 2022-04-20

TNBC

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04192903 2022-04-20

Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04517292 2020-08-18

GEP

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03644589 2019-04-26

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01091454 2018-05-08

Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

48 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01910844 2016-10-11

META2

Phase 2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01672671 2015-11-03

BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT00930930 2015-05-07

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2 Completed

145 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01928680 2015-02-23

Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer

Phase 2 Unknown

33 enrolled 5 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00601159 2011-07-04

Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms